TrialClinical lung cancer2020

Phase I/II Trial of Immunotherapy With Durvalumab and Tremelimumab With Continuous or Intermittent MEK Inhibitor Selumetinib in NSCLC: Early Trial Report.

Pierre-Olivier Gaudreau et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.